Vahri Beaumont

University of California, Los Angeles, Los Angeles, CA 
synaptic transmission, signalling
"Vahri Beaumont"
Mean distance: 13.5 (cluster 32)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Beaumont V, Mrzljak L, Dijkman U, et al. (2016) The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. Experimental Neurology
Sutcliffe JS, Beaumont V, Watson JM, et al. (2014) Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female cynomolgus monkeys (Macaca fascicularis). Plos One. 9: e102449
Beaumont V, Park L, Rassoulpour A, et al. (2014) The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease. Plos Currents. 6
Mielcarek M, Landles C, Weiss A, et al. (2013) HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. Plos Biology. 11: e1001717
Mielcarek M, Seredenina T, Stokes MP, et al. (2013) HDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivo. Plos One. 8: e80849
Bürli RW, Luckhurst CA, Aziz O, et al. (2013) Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. Journal of Medicinal Chemistry. 56: 9934-54
Heikkinen T, Lehtimäki K, Vartiainen N, et al. (2012) Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. Plos One. 7: e50717
Beconi M, Aziz O, Matthews K, et al. (2012) Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. Plos One. 7: e44498
Orru M, Bakešová J, Brugarolas M, et al. (2011) Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists. Plos One. 6: e16088
Bürli RW, Thomas E, Beaumont V. (2010) The role of histone deacetylases in neurodegenerative diseases and small-molecule inhibitors as a potential therapeutic approach Topics in Medicinal Chemistry. 6: 1-56
See more...